



Comparison of Efficacy and Safety of Different Medication Protocols in Patients with Immunoglobulin G4-Related Disease Based on Follow-up Time: A Systematic Review and Network Meta-analysis

ABSTRACT

Background/Aims: Glucocorticoids (GCs) and disease-modifying anti-rheumatic drugs (DMARDs) are commonly used drugs in the treatment of immunoglobulin G4-related disease (IgG4-RD). However, no broad consensus is available on their intervention effects. Therefore, the efficacy and safety of different medication protocols in the treatment of IgG4-RD were assessed in this systematic review and network meta-analysis.

Materials and Methods: This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. RStudio and Stata 15.1 were used for data analysis.

Results: The results showed that in terms of improvement of remission rates, GCs+DMARDs had the strongest overall efficacy [surface under the cumulative ranking curve (SUCRA)=82.9%], and DMARDs were the most effective within 12 months during follow-up (SUCRA=82.5%), while GCs+DMARDs were the most effective over 12 months during follow-up (SUCRA=83.2%). In terms of reduction of relapse rates, the overall efficacy of GCs+DMARDs was the strongest (SUCRA=83.5%), and GCs+DMARDs performed the best both within and over 12 months during follow-up. The adverse reaction rates were 38.9%, 5.3%, and 33.3%, respectively, among patients treated with GCs+DMARDs, DMARDs, and GCs.

Conclusion: The GCs+DMARDs are recommended for short-term improvement of remission rates and reduction of relapse rates, as well as for achieving long-term efficacy.

Keywords: DMARDs, follow-up time, glucocorticoids, IgG4-related disease, network meta-analysis

Introduction

Immunoglobulin G4 (IgG4)-related disease (IgG4-RD), an immune-mediated systemic fibroinflammatory disease, is characterized by active multi-organ lesions, IgG4-positive plasma cell infiltration, and elevated serum IgG4 concentrations.¹⁻³ Patients with IgG4-RD usually present with enlargement and fibrosis of a single or multiple organs or tissues, including the pancreas, bile ducts, salivary glands, retroperitoneum, sinuses, and orbits,^{4,5} which can lead to symptoms of obstruction or compression and irreversible organ damage. Therefore, early identification and prompt appropriate treatment of IgG4-RD are critical, and tumor-like lesions or even organ failure may occur

Yanwen Liu^{ID}
Xianghui Fu^{ID}
Youqun Zhang^{ID}
Yan Zheng^{ID}
Junfeng Jia^{ID}
Zhaohui Zheng^{ID}
Ping Zhu^{ID}
Kui Zhang^{ID}

Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China

Corresponding author:
Kui Zhang
✉ zhk100@fmmu.edu.cn

Received date: August 22, 2025
Revision requested:
September 29, 2025
Last revision received:
October 13, 2025
Accepted: October 21, 2025
Publication Date: January 16, 2026

Cite this article as: Liu Y, Fu X, Zhang Y, et al. Comparison of efficacy and safety of different medication protocols in patients with immunoglobulin G4-related disease based on follow-up time: A systematic review and network meta-analysis. *ArchRheumatol*. 2026;41(1):3-13.



if no prompt and effective treatment is available,⁶ greatly affecting the quality of life and longevity of patients.

Glucocorticoids (GCs) and disease-modifying antirheumatic drugs (DMARDs) are the commonly used drugs in the treatment of IgG4-RD nowadays. In particular, GCs can rapidly ameliorate clinical symptoms and reduce levels of blood biochemical indicators since most patients are sensitive to steroid therapy, but up to 40% of patients experience a relapse within the first year post-treatment.⁷ In addition, long-term use of GCs may lead to a series of adverse reactions, such as infection, glucose intolerance, and osteoporosis.⁸ Increasingly more novel DMARDs have been applied in the treatment of IgG4-RD in recent years, such as abatacept and iguratimod,^{9,10} achieving favorable effects. Different conclusions were made in several studies regarding the efficacy of GCs+DMARDs vs. GCs on IgG4-RD. Some studies held that GCs+DMARDs are superior to GCs in controlling the condition and reducing relapse,^{11,12} while some showed no difference in the relapse rate between the 2 medication protocols.^{13,14}

In addition, most studies disagree on which medication protocol is the most effective at different follow-up times. Research suggested that the remission rate is higher when DMARDs are used than when GCs or GCs+DMARDs are used at 6 months during follow-up,¹⁵ while others showed that DMARDs produce a lower remission rate than GCs over 5 years during follow-up.¹⁶ Therefore, a network meta-analysis (NMA) was carried out on 4 different

medication protocols (GCs, DMARDs, GCs+DMARDs, and watchful waiting) to compare their efficacy in the treatment of IgG4-RD, and subgroup analyses were performed based on different follow-up times, thereby clarifying the efficacy and safety of each protocol.

Methods

Study Registration

This NMA was conducted fully following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)¹⁷ to improve the quality of reporting of meta-analyses, and the PRISMA checklist is available in Supplementary Table 1. The study protocol had been registered with PROSPERO (CRD42024521672).

Literature Search Strategy

A search was carried out in 4 English databases (PubMed, Embase, Web of Science, and Cochrane Library) in this NMA from inception to December 25, 2024. Medical subject headings plus text words were used in the search, including “IgG4-related disease,” “glucocorticoids,” “immunosuppressants,” “biologics,” “disease-modifying antirheumatic drugs,” “rituximab,” “retrospective studies,” “prospective studies,” “cohort studies,” and “case-control studies.” The search strategy was modified according to the database characteristics and Participant, Intervention, Comparison, Outcome, and Study (PICOS) principle.¹⁸ A manual search was also conducted to identify potentially missing relevant studies. The complete search method is described in Supplementary Table 2.

Eligibility Criteria

All included studies followed the PICOS principle:

Participant: 1) Patients diagnosed with IgG4-RD based on the recognized diagnostic criteria at the time of publication, regardless of gender, race, ethnicity, duration of disease, and etiology; 2) Patient age ≥ 14 years.

Intervention: GCs, DMARDs, or GCs+DMARDs were given to the patients in the intervention group. The duration of treatment was at least 3 months. The DMARDs included conventional DMARDs (cDMARDs) and biological DMARDs (bDMARDs), the former of which included drugs such as mycophenolate mofetil, cyclophosphamide, and methotrexate, and the latter of which included drugs such as rituximab (RTX) and abatacept.

Comparison: Only watchful waiting was adopted in the control group. Watchful waiting was defined as temporarily performing no immediate treatment after IgG4-RD diagnosis but observing disease progression through regular monitoring and follow-up.

Outcome: 1) Remission rate. Disease remission was defined as improvement in related symptoms of IgG4-RD, reduction in the number of involved lesions, or a decrease in the IgG4-RD response index of ≥ 2 from baseline;^{19,20} 2) Relapse rate. Disease relapse was defined as recurrence of enlargement of involved organs and/or worsening of

MAIN POINTS

- *First comprehensive network meta-analysis comparing the efficacy and safety of 4 treatment protocols (glucocorticoids (GCs), disease-modifying antirheumatic drugs (DMARDs), GCs+DMARDs, watchful waiting) for immunoglobulin G4-related disease (IgG4-RD) with stratified analysis by follow-up duration (\leq / $>$ 12 months).*
- *Combination therapy superiority: The GCs+DMARDs demonstrated the strongest overall efficacy for improving remission rates surface under the cumulative ranking curve (SUCRA=82.9%) and reducing relapse rates (SUCRA=83.5%), outperforming monotherapies and watchful waiting across all time frames.*
- *Safety profile: The DMARDs had the lowest adverse reaction rate (5.3%), significantly lower than GCs (33.3%) and GCs+DMARDs (38.9%). Common adverse events included infections, glucose intolerance, and gastrointestinal reactions.*
- *Clinical recommendation: The GCs+DMARDs is recommended as the preferred regimen for both short-term disease control and sustained long-term management of IgG4-RD, balancing efficacy with manageable toxicity.*

imaging findings, with or without a re-increase in serum IgG4 levels;²¹ 3) Adverse reactions.

Study: Observational studies. Minimum sample size ≥ 5 .

Exclusion criteria: 1) Meta-analyses, reviews, or guidelines; 2) conference papers, replies, or comments; 3) case reports; 4) animal or in vitro experimental studies; 5) studies published in a language other than English; 6) duplicate publications; 7) incorrect or incomplete data; and 8) unavailable full text.

Data Extraction

After duplicate publications were eliminated using EndNote20, 2 reviewers were independently responsible for screening titles and abstracts from the search results, and then conducting a full-text search to identify eligible studies based on the inclusion and exclusion criteria. In case of disagreement, they could discuss or consult a third reviewer for resolution. A standardized data collection form was used for data extraction, including main author, country, and year of publication of the included studies, sample size, mean age, and clinical characteristics of the participants, treatment protocols for IgG4-RD, duration of follow-up, remission and relapse rates, and all adverse reactions (infections, osteoporosis, diabetes mellitus, hypertension, and hepatic dysfunction) in each group.

Quality Assessment

The quality assessment of the included studies was performed by 2 reviewers using the Newcastle–Ottawa Scale (NOS),²² covering study population selection, comparability, and outcome. The semi-quantitative principle of a star scale was used with a maximum of 9 stars, and each item was assessed at a maximum of 1 star, except for comparability which was assessed at a maximum of 2 stars. A higher score suggested a higher quality of study. Any disagreements were resolved by discussion with a third reviewer.

Synthesis Methods

Bayesian NMA was carried out, and the Stata 15.1 (StataCorp LLC; College Station, TX, USA) “network” command and the RStudio 4.3.2 (Posit PBC; Boston, MA, USA) “gemtc” and “coda” packages were used for statistical analyses. The Markov Chain Monte Carlo method was utilized for modeling, with 4 simultaneous Markov chains running and the number of iterations set to 20 000, and the modeling was completed after 50 000 simulation iterations. For dichotomous variables, relative risk (RR) was used as the effect size index, along with a 95% CI, and the difference was considered statistically significant between 2 groups when the 95% CI of RR did not contain 1. Whether the overall consistency and inconsistency of the model fit were uniform was compared by the deviance information criterion (DIC). The DIC difference < 5 was deemed uniform between overall consistency and inconsistency, and vice versa. The nodal split method was used for further local consistency testing in the case of

a closed loop, and $P < .05$ suggested local inconsistency in 2 interventions. Heterogeneity was assessed using the I^2 statistic, and the estimated $I^2 > 50\%$ suggested high heterogeneity. In addition, the interventions were ranked based on the surface under the cumulative ranking curve (SUCRA), and the differences in their efficacy were displayed using a rankogram. The closer the SUCRA value was to 100%, the higher the likelihood that the intervention was the optimal protocol. Publication bias tests were performed using the funnel plot on the results that included more than 10 studies. Subgroup analyses were also conducted on the relapse and remission rates when different medication protocols were adopted at different follow-up time.

Results

Study Selection

Initially, 1766 records were retrieved using the literature search strategy. After 676 duplicates were deleted, 1090 records were obtained, of which 863 were excluded based on the title and abstract. After the full-text search, 34 eligible studies were acquired finally,^{6,9,11,12,14-16,19,23-48} and were included in this study, all of which had been published. The literature screening procedure is described in Figure 1.

Study Characteristics


In the 34 observational studies included, 4337 patients underwent one of the 4 treatments for IgG4-RD. These studies were from Asia ($n=21$), North America ($n=7$), and Europe ($n=6$). The duration of follow-up was 3-240 months. All studies were published in English from 2008 to 2023. The characteristics of the included studies are shown in Supplementary Table 3.

Quality Assessment Results

The quality of the included studies was evaluated using the NOS and assessed the selection bias of each included study from the “Selection,” “Comparability,” and “Outcome” domains. The highest score in the “Selection” domain was 4, and all included studies were scored ≥ 3 ; the highest score in the “Comparability” domain was 2, and 16 out of the 34 included studies were scored 2; the highest score in the “Outcome” domain was 3, and all included studies were scored ≥ 2 . The results of the quality assessment of the included studies using NOS revealed that all studies had high methodological quality, with 13 studies scoring 7, 14 studies scoring 8, and 7 studies scoring 9. The risk of bias for the included studies is displayed in Supplementary Table 3.

Meta-Analysis

Remission: Seventeen studies involving 2749 patients were included.^{9,11,12,15,16,19,23,28,29,32,37,43-46,48} The network diagram comparing the overall remission rates among medication protocols is shown in Figure 2A. The network diagram comparing the remission rates within 12 months (included) during follow-up and the network diagram



comparing the remission rates over 12 months during follow-up are shown in Supplementary Figure 1A, 2A, respectively.

It was found by the meta-analyses on the overall remission rates of different medication protocols that GCs+DMARDs (RR=1.65, 95% CI: 1.23-2.25), GCs (RR=1.46, 95% CI: 1.13-1.92), and DMARDs (RR=1.62, 95% CI: 1.14-2.33) all achieved higher remission rates than watchful waiting

(Figure 2C). In the rankogram, GCs+DMARDs ranked first (SUCRA=82.9%), followed by DMARDs (74.0%) and GCs (42.7%) (Figure 2B).

The results of meta-analyses on the remission rates within 12 months during follow-up revealed that the remission rates of GCs+DMARDs (RR=1.94, 95% CI: 1.07-3.49) and DMARDs (RR=2.09, 95% CI: 1.09-4.11) were higher than watchful waiting (Supplementary Figure 1C).




Figure 2. Network meta-analysis results for the overall remission rates. (A): Network diagram. Each node represents 1 medication protocol, and its size is proportional to the total number of patients receiving this medication protocol. Each line represents a head-to-head comparison, and its width is proportional to the number of studies comparing the connected protocols. (B): Cumulative probability ranking curve of different interventions; different interventions are ranked based on the surface under the cumulative ranking curve (SUCRA). The closer the SUCRA value is to 100%, the higher the likelihood that the intervention is the optimal protocol. (C): Forest plot. GCs, glucocorticoids; DMARDs, disease-modifying antirheumatic drugs; WW, Watchful waiting.

In the rankogram, DMARDs ranked first (SUCRA=82.5%), followed by GCs+DMARDs (73.3%) and GCs (42.2%) (Supplementary Figure 1B).


By the meta-analyses on the remission rates over 12 months during follow-up, no statistically significant difference was found in the pairwise comparison of medication protocols ($P > .05$) (Supplementary Figure 2C). In the rankogram, GCs+DMARDs ranked first (SUCRA=83.2%), followed by DMARDs (54.8%) and GCs (53.0%) (Supplementary Figure 2B).

Relapse: Twenty-seven studies involving 4106 patients were included.^{11,12,14,15,23-48} The network diagram comparing the overall relapse rates among medication protocols is shown in Figure 3A. The network diagram comparing the

relapse rates within 12 months during follow-up and the network diagram comparing the relapse rates over 12 months during follow-up are shown in Supplementary Figure 3A, 4A, respectively.

It was found by the meta-analyses on the overall relapse rates of different medication protocols that GCs+DMARDs achieved lower relapse rates than GCs (RR=0.58, 95% CI: 0.43-0.77) (Figure 3C). In the rankogram, GCs+DMARDs ranked first (SUCRA=83.5%), followed by watchful waiting (64.5%) and DMARDs (43.9%) (Figure 3B).

The results of meta-analyses on the relapse rates within 12 months during follow-up revealed that the relapse rates of GCs+DMARDs were lower than GCs (RR=0.49, 95% CI: 0.33-0.71) (Supplementary Figure 3C). In the rankogram,



GCs+DMARDs ranked first (SUCRA=91.7%), followed by DMARDs (48.8%) and GCs (9.5%) (Supplementary Figure 3B).

The results of meta-analyses on the relapse rates over 12 months during follow-up revealed that the relapse rates of GCs+DMARDs were lower than GCs (RR=0.64, 95% CI: 0.41-0.99) (Supplementary Figure 4C). In the rankogram, GCs+DMARDs ranked first (SUCRA=74.4%), followed by watchful waiting (66.3%) and DMARDs (45.3%) (Supplementary Figure 4B).

Adverse Reactions: Adverse reactions occurring during treatment with 3 different medication protocols were mentioned and detailed in 6 studies,^{11,12,33,36,37,47} including infections, gastrointestinal reactions, impaired hepatic function, and glucose intolerance (Table 1). The adverse reaction rates were 38.9%, 5.3%, and 33.3%, respectively, among patients treated with GCs+DMARDs, DMARDs,

Table 1. The Occurrence of Adverse Reactions of 3 Different Medication Protocols During Treatment			
Medication Protocol	GCs + DMARDs	DMARDs	GCs
Number of included studies	6	1	5
Sample size	285	19	252
Infections	43	1	38
Glucose intolerance	31	0	25
Gastrointestinal reactions	23	0	12
Impaired hepatic function	6	0	6
Hypertension	2	0	3
Leukopenia	5	0	0
Myelosuppression	1	0	0
Total probability, %	38.9	5.3	33.3





Figure 4. Funnel plots of outcomes. (A): the overall remission rates; (B): the overall relapse rates. GCs, glucocorticoids; DMARDs, disease-modifying antirheumatic drugs; WW, Watchful waiting.

and GCs. The qualitative meta-analysis revealed that GCs-containing protocols (GCs and GCs+DMARDs) most frequently induced metabolic toxicity (e.g., glucose intolerance) and gastrointestinal toxicity. In contrast, hematologic events (e.g., leukopenia) were reported only for GCs+DMARDs (Supplementary Table 4). Despite limited data, these findings highlighted organ-specific risks, particularly for GCs-based protocols.

Publication Bias: More than 10 studies were included in the analysis of the overall remission and relapse rates, so the publication bias was assessed by funnel plots, with points of different colors indicating comparisons among the 4 medication protocols. As shown in the funnel plots, the remission rates displayed no publication bias (Figure 4A), whereas the yellow line segments of the relapse rates tended to be parallel to the X-axis, indicating possible publication bias (Figure 4B).

Sensitivity Analyses: Network meta-analysis was carried out on the overall remission and relapse rates using random-effects and fixed-effects models, respectively, and the similarities in the total residual deviance (totresdev), penalty term for deviance (pD), and DIC values were observed. The results showed that the values of the 3 parameters were similar between the 2 models (overall remission rate: fixed-effects vs. random-effects: totresdev=39.93 vs. 40.07, DIC=69.35 vs. 67.84, pD=29.42 vs. 27.77. Overall relapse rate: fixed-effects vs. random-effects: totresdev=56.80 vs. 57.36, DIC=103.52 vs. 102.46, pD=46.72 vs. 45.10), suggesting good similarity in the included studies and stable and reliable data.

Subgroup Analyses: To assess the impact of demographics on the results, subgroup analyses were performed by region. There were 21 studies including 2803 patients in Asia, 7 studies including 458 patients in North America, and 6 studies including 1076 patients in Europe. The number of studies in North America and Europe was too small to conduct an NMA, so both were combined as non-Asian studies. To determine the presence or absence of regional differences in the distribution of involved organs, organ involvement in the included studies was statistically analyzed. Sixteen studies reported single-organ involvement, while the remaining 18 studies reported systemic organ involvement specifically in the Asian cohort (10 studies) and non-Asian cohort (8 studies); the top 10 involved organs were largely the same in both cohorts (Supplementary Table 5). Both Asian studies (SUCRA=80.4%) and non-Asian studies (SUCRA=75.8%) revealed that GCs+DMARDs were most effective in improving the overall remission rate, and both Asian studies (SUCRA=92.2%) and non-Asian studies (SUCRA=92.9%) revealed that GCs+DMARDs performed best in reducing the overall relapse rate. The results of subgroup analyses were consistent with those of the original studies (Supplementary Table 6). Heterogeneity analyses showed that the overall I^2 values for the remission

and relapse rates were 46.3% and 33.3% in Asian studies, and 48.3% and 0% in non-Asian studies, respectively, all less than 50%, suggesting that the results were stable and reliable.

To assess the impact of different DMARDs on study results, subgroup analyses were conducted on bDMARDs and cDMARDs. The meta-analysis revealed that the overall remission rates of GCs+cDMARDs (RR=1.72, 95% CI: 1.26-2.39), GCs alone (RR=1.50, 95% CI: 1.14-2.00), and bDMARDs alone (RR=2.01, 95% CI: 1.28-3.18) were all higher than that of watchful waiting (Supplementary Table 7). In the rankogram, bDMARDs alone ranked first (SUCRA=88.8%), followed by GCs+cDMARDs (71.4%) and GCs+bDMARDs (58.0%). Besides, the overall relapse rate of GCs+cDMARDs was lower than that of GCs alone (RR=0.50, 95% CI: 0.34-0.70) (Supplementary Table 7). In the rankogram, GCs+bDMARDs ranked first (SUCRA=80.51%), followed by GCs+cDMARDs (65.0%) and bDMARDs alone (63.7%). Subgroup analyses on different DMARDs also revealed that GCs+bDMARDs or GCs+cDMARDs raised the remission rate and reduced the relapse rate.

Discussion

This NMA included 34 observational studies involving 4337 IgG4-RD patients, and they were treated with GCs, DMARDs, GCs+DMARDs, or watchful waiting. This is the first study that comprehensively compared the efficacy and safety of the 4 medication protocols in the treatment of IgG4-RD within and over 12 months during follow-up. The results showed that in terms of improvement of remission rates, GCs+DMARDs had the strongest overall efficacy, and DMARDs had a higher efficacy within 12 months during follow-up, while GCs+DMARDs were the most effective over 12 months during follow-up. In terms of reduction of relapse rates, the overall efficacy of GCs+DMARDs was the strongest, and GCs+DMARDs performed the best both within and over 12 months during follow-up. Moreover, DMARDs had a lower incidence of adverse reactions in comparison with GCs and GC+DMARDs.

Currently, the treatment of IgG4-RD consists of remission induction and maintenance therapy stages. The former aims to reduce focal inflammation and rapidly relieve symptoms, while the latter aims to maintain disease remission. In this study, the remission rates of different medication protocols in the 2 stages were explored based on the follow-up time. It was found that GCs+DMARDs had the strongest overall efficacy in improving the remission rate. A meta-analysis showed that GCs plus immunosuppressants can achieve higher remission rates than GCs;⁴⁹ multiple studies^{50,51} suggested that GCs plus RTX have a higher remission rate than RTX, consistent with the findings. Besides, DMARDs achieved the best effect within 12 months during follow-up. Rituximab was the major type of DMARDs in the included studies, and its

ability to effectively treat IgG4-RD and rapidly relieve clinical symptoms has been verified.⁵² When used in the treatment of IgG4-RD, RTX can achieve a remission rate of more than 90%, and the remission rate has no increase when combined with GCs,¹⁹ which may contribute to the higher remission rate of DMARDs. In addition, DMARDs were mostly used in mild cases in the included studies, which may also account for the highest remission rate of DMARDs. In addition, GCs+DMARDs were the most effective over 12 months during follow-up. Immunosuppressants were the major type of DMARDs in the included studies. As reported by a meta-analysis covering 15 studies, GCs plus immunosuppressants achieve higher remission rates than GCs in the treatment of IgG4-RD,⁵³ consistent with the findings in this paper.

The relapse rate of IgG4-RD increases with the extension of follow-up time,⁴⁰ and the course of the disease exhibits a “relapse-remission” pattern,⁵⁴ which is prone to repeated attacks if not properly treated. In this study, GCs + DMARDs produced lower relapse rates than GCs at different follow-up times. The conclusions regarding the relapse rates in different medication protocols vary across studies. Some studies held that GCs + DMARDs can reduce relapse compared with GCs,³³ while some suggested that the relapse rate has no difference between the 2 protocols.²⁶ This study demonstrated that GCs + DMARDs yielded a lower relapse rate than GCs. A randomized controlled clinical study revealed that GCs + DMARDs are superior to GCs in preventing relapse of IgG4-RD, consistent with the results in this paper.⁵⁵ In the treatment of IgG4-RD, GCs work primarily by reducing inflammatory factors to relieve symptoms and are usually tapered off gradually due to many adverse reactions during long-term use, so relapse occurs easily.^{56,57} With a synergistic effect, GCs + DMARDs may contribute to the sustained control of tissue inflammation and reduce the relapse rate in IgG4-RD patients. Publication bias was indeed present in the assessment of relapse rates, which might result from the region of publication, the grade of periodicals, and sources of funding.

This NMA had several limitations. First, the sample size was small in some results, and differences were present in the dosage of GCs and patient baseline data, so larger-scale, high-quality randomized controlled studies are required to enhance the quality of evidence in the future. Second, only English-language studies were included. Moreover, the risk of confounding bias introduced by observational studies and the between-study heterogeneity in diagnostic criteria posed significant challenges to internal validity and inter-study comparability, thus increasing uncertainty in efficacy and safety estimates and weakening the reliability of comparison between different medication protocols. Random-effects models and sensitivity analyses were employed to mitigate these issues, but the inherent limitations of these methodologies cannot be fully eliminated. Therefore, the results of this NMA should be regarded as the best estimate under the current evidence base, and the conclusions should

be interpreted with caution. In the future, high-quality randomized controlled trials (RCTs) with standardized diagnostic criteria are required for validation. Finally, due to the limited reporting quality of the original studies, only 1 study was included for the adverse reactions of DMARDs alone, with a small sample size, so the results may not be robust. Meanwhile, none of the included studies reported renal events, indicating gaps in safety monitoring. Therefore, future studies should prioritize prospective safety monitoring.

In conclusion, this NMA demonstrated that GCs + DMARDs can maintain a higher remission rate and the lowest relapse rate than other medication protocols. The GCs + DMARDs are recommended for both short-term and long-term medication. Currently, increasingly more treatment options for IgG4-RD are available, and individualized and precise treatment is the direction of development in this field. Large-scale RCTs are needed in the future to validate the relative efficacy of different medication protocols. Given the great heterogeneity in the natural course of IgG4-RD across different involved organs, organ-specific clinical trials or registry studies are also required to provide detailed data for individualized treatment strategies.

Data Availability Statement: The data that support the findings of this study are available on request from the corresponding author.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – Y.L., K.Z.; Design – Y.L., X.F., Y.Z., K.Z.; Supervision – Z.Z., P.Z., K.Z.; Resources – Y.L., J.J., Y.Z.; Materials – Y.L., X.F., Y.Z.; Data Collection and/or Processing – Y.L., X.F.; Analysis and/or Interpretation – Y.L., Y.Z., K.Z.; Literature Search – Y.L., Y.Z., J.J.; Writing – Y.L., X.F., Y.Z., K.Z.; Critical Review – Z.Z., P.Z., K.Z.

Declaration of Interests: The authors have no conflicts of interest to declare.


Funding: The study was funded by the National Natural Science Foundation of China (No. 81871273), the Quick Response Project of Fourth Military Medical University (No. 2023KXKT083), and the Key Industry Innovation Chain of Shaanxi Province's Key R&D Program (No. 2023-ZDLSF-41).

References


1. Bozzalla Cassione E, Stone JH. IgG4-related disease. *Curr Opin Rheumatol*. 2017;29(3):223-227. [\[CrossRef\]](#)
2. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. *Mod Pathol*. 2012;25(9):1181-1192. [\[CrossRef\]](#)
3. Yadlapati S, Verheyen E, Efthimiou P. IgG4-related disease: a complex under-diagnosed clinical entity. *Rheumatol Int*. 2018;38(2):169-177. [\[CrossRef\]](#)
4. Li PH, Ko KL, Ho CT, et al. Immunoglobulin G4-related disease in Hong Kong: clinical features, treatment practices, and its association with multisystem disease. *Hong Kong Med J*. 2017;23(5):446-453. [\[CrossRef\]](#)

5. Lian L, Wang C, Tian JL. IgG4-related retroperitoneal fibrosis: a newly characterized disease. *Int J Rheum Dis*. 2016;19(11):1049-1055. [\[CrossRef\]](#)
6. Sekiguchi H, Horie R, Kanai M, Suzuki R, Yi ES, Ryu JH. IgG4-related disease: retrospective analysis of one hundred sixty-six patients. *Arthritis Rheumatol*. 2016;68(9):2290-2299. [\[CrossRef\]](#)
7. Brito-Zerón P, Kostov B, Bosch X, Acar-Denizli N, Ramos-Casals M, Stone JH. Therapeutic approach to IgG4-related disease: A systematic review. *Med (Baltim)*. 2016;95(26):e4002. [\[CrossRef\]](#)
8. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. *Expert Opin Drug Saf*. 2016;15(4):457-465. [\[CrossRef\]](#)
9. Matza MA, Perugino CA, Harvey L, et al. Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study. *Lancet Rheumatol*. 2022;4(2):e105-e112. [\[CrossRef\]](#)
10. Zhang P, Gong Y, Liu Z, et al. Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: a prospective clinical trial. *Int J Rheum Dis*. 2019;22(8):1479-1488. [\[CrossRef\]](#)
11. Yunyun F, Yu P, Panpan Z, et al. Efficacy and safety of low dose mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. *Rheumatol (Oxf Engl)*. 2019;58(1):52-60. [\[CrossRef\]](#)
12. Yunyun F, Yu C, Panpan Z, et al. Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. *Sci Rep*. 2017;7(1):6195. [\[CrossRef\]](#)
13. Campochiaro C, Ramirez GA, Bozzolo EP, et al. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. *Scand J Rheumatol*. 2016;45(2):135-145. [\[CrossRef\]](#)
14. Zhang X, Zeng Z, Tian H, et al. Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study. *Clin Exp Med*. 2023;23(7):3527-3538. [\[CrossRef\]](#)
15. Gan L, Luo X, Fei Y, et al. Long-term outcomes of IgG4-related ophthalmic disease in a Chinese IgG4-related disease cohort. *Front Med (Lausanne)*. 2021;8:784520. [\[CrossRef\]](#)
16. Ebbo M, Daniel L, Pavic M, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. *Med (Baltim)*. 2012;91(1):49-56. [\[CrossRef\]](#)
17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. [\[CrossRef\]](#)
18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700. [\[CrossRef\]](#)
19. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. *Ann Rheum Dis*. 2015;74(6):1171-1177. [\[CrossRef\]](#)
20. Wallace ZS, Khosroshahi A, Carruthers MD, et al. An international multispecialty validation study of the IgG4-related disease responder index. *Arthritis Care Res (Hoboken)*. 2018;70(11):1671-1678. [\[CrossRef\]](#)
21. Shirakashi M, Yoshifuji H, Kodama Y, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. *Sci Rep*. 2018;8(1):10262. [\[CrossRef\]](#)
22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25(9):603-605. [\[CrossRef\]](#)
23. Fernández-Codina A, Pinilla B, Pinal-Fernández I, et al. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index. *Jt Bone Spine*. 2018;85(6):721-726. [\[CrossRef\]](#)
24. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. *Gastroenterology*. 2008;134(3):706-715. [\[CrossRef\]](#)
25. Kubota K, Watanabe S, Uchiyama T, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. *J Gastroenterol*. 2011;46(6):834-842. [\[CrossRef\]](#)
26. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. *Gut*. 2013;62(11):1607-1615. [\[CrossRef\]](#)
27. Huggett MT, Culver EL, Kumar M, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. *Am J Gastroenterol*. 2014;109(10):1675-1683. [\[CrossRef\]](#)
28. Nada R, Ramachandran R, Kumar A, et al. IgG4-related tubulointerstitial nephritis: A prospective analysis. *Int J Rheum Dis*. 2016;19(7):721-729. [\[CrossRef\]](#)
29. Sun X, Liu H, Feng R, et al. Biopsy-proven IgG4-related lung disease. *BMC Pulm Med*. 2016;16:20. [\[CrossRef\]](#)
30. Wallace ZS, Mattoo H, Mahajan VS, et al. Predictors of disease relapse in IgG4-related disease following rituximab. *Rheumatol (Oxf Engl)*. 2016;55(6):1000-1008. [\[CrossRef\]](#)
31. Chen YC, Chan HH, Lai KH, Tsai TJ, Hsu PI. Type 1 (IgG4-related) autoimmune pancreatitis: experiences in a medical center in southern Taiwan within the past 10 years. *Adv in Digestive Medicine*. 2017;4(2):61-70. [\[CrossRef\]](#)
32. Karadağ Ö, Erden A, Ayhan EA, et al. The clinical features and outcomes of Turkish patients with IgG4-related disease: a single-center experience. *Turk J Med Sci*. 2017;47(5):1307-1314. [\[CrossRef\]](#)
33. Hong X, Zhang YY, Li W, et al. Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents. *Arthritis Res Ther*. 2018;20(1):12. [\[CrossRef\]](#)
34. Karim AF, Bansie RD, Rombach SM, et al. The treatment outcomes in IgG4-related disease. *Neth J Med*. 2018;76(6):275-285.
35. Park J, Lee MJ, Kim N, et al. Risk factors for extraocular involvement and treatment outcomes in patients with IgG4-related ophthalmic disease. *Br J Ophthalmol*. 2018;102(6):736-741. [\[CrossRef\]](#)
36. Wallwork R, Wallace Z, Perugino C, Sharma A, Stone JH. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. *Med (Baltim)*. 2018;97(42):e12631. [\[CrossRef\]](#)
37. Wang L, Zhang P, Wang M, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. *Arthritis Res Ther*. 2018;20(1):65. [\[CrossRef\]](#)
38. Xin L, Meng QQ, Hu LH, et al. Prediction and management for relapse of Type 1 autoimmune pancreatitis after initial steroid treatment: A long-term follow-up from china. *Pancreas*. 2018;47(9):1110-1114. [\[CrossRef\]](#)
39. Peng Y, Li JQ, Zhang PP, et al. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study. *J Intern Med*. 2019;286(5):542-552. [\[CrossRef\]](#)


40. Liu Y, Zeng Q, Zhu L, et al. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort. *Rheumatol (Oxf Engl)*. 2020;59(8):2115-2123. [\[CrossRef\]](#)
41. Phaopraphat K, Ngamjanyaporn P, Narongroeknawin P, Kasitanon N, Katchamart W. Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease. *Int J Rheum Dis*. 2020;23(11):1468-1473. [\[CrossRef\]](#)
42. Peng L, Lu H, Zhou J, et al. Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study. *Arthritis Res Ther*. 2021;23(1):102. [\[CrossRef\]](#)
43. Zongfei J, Lingying M, Lijuan Z, et al. Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study. *Clin Rheumatol*. 2021;40(6):2293-2300. [\[CrossRef\]](#)
44. An W, Wu Z, Li M, et al. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients. *Orphanet J Rare Dis*. 2022;17(1):307. [\[CrossRef\]](#)
45. Kubota K, Kamisawa T, Nakazawa T, et al. Steroid therapy still plays a crucial role and could serve as a bridge to the next promising treatments in patients with IgG4-related sclerosing cholangitis: results of a Japanese Nationwide Study. *J Hepatobil Pancreat Sci*. 2022;29(8):884-897. [\[CrossRef\]](#)
46. Son KY, Woo KI, Kim YD. Clinical outcomes of IgG4-related ophthalmic disease and idiopathic sclerosing orbital inflammation. *Ophthalm Plast Reconstr Surg*. 2022;38(1):34-39. [\[CrossRef\]](#)
47. Chaba A, Devresse A, Audard V, et al. Clinical and prognostic factors in patients with IgG4-related kidney disease. *Clin J Am Soc Nephrol*. 2023;18(8):1031-1040. [\[CrossRef\]](#)
48. Overbeek KA, Poulsen JL, Lanzillotta M, et al. Type 1 autoimmune pancreatitis in Europe: clinical profile and response to treatment. *Clin Gastroenterol Hepatol*. 2024;22(5):994-1004.e10. [\[CrossRef\]](#)
49. Alsalamah NI, Alhrabi B, Alhumaily N, AlHadidi R, Basu-brain LS, Al Asmari Z. Efficacy and safety of glucocorticoid monotherapy versus the combination of glucocorticoid and immunosuppressive agents for immunoglobulin G4-related disease: a systematic review and meta-analysis. *Cureus*. 2023;15(10):e47099. [\[CrossRef\]](#)
50. Yamamoto M. B cell targeted therapy for immunoglobulin G4-related disease. *Immunol Med*. 2021;44(4):216-222. [\[CrossRef\]](#)
51. Choi SJ, Ahn SM, Oh JS, et al. Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease. *PLOS One*. 2023;18(3):e0282852. [\[CrossRef\]](#)
52. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. *Arthritis Rheum*. 2010;62(6):1755-1762. [\[CrossRef\]](#)
53. Omar D, Chen Y, Cong Y, Dong L. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. *Rheumatol (Oxf Engl)*. 2020;59(4):718-726. [\[CrossRef\]](#)
54. Miki M, Fujimori N, Oono T, et al. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: A single-center retrospective study of 115 patients. *J Dig Dis*. 2019;20(3):152-158. [\[CrossRef\]](#)
55. Wang Y, Zhao Z, Gao D, et al. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: a randomized clinical trial. *Semin Arthritis Rheum*. 2020;50(6):1513-1520. [\[CrossRef\]](#)
56. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. *Clin Gastroenterol Hepatol*. 2009;7(10):1089-1096. [\[CrossRef\]](#)
57. Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. *Gut*. 2013;62(12):1771-1776. [\[CrossRef\]](#)



Supplementary Figure 1. Network meta-analysis results for the remission rates within 12 months. (A): Network diagram; (B): Cumulative probability ranking curve of different interventions; (C): Forest plot. GCs, glucocorticoids; DMARDs, disease-modifying antirheumatic drugs; WW, Watchful waiting.




Supplementary Figure 2. Network meta-analysis results for the remission rates over 12 months. (A): Network diagram; (B): Cumulative probability ranking curve of different interventions; (C): Forest plot. GCs, glucocorticoids; DMARDs, disease-modifying antirheumatic drugs; WW, Watchful waiting.




Supplementary Figure 3. Network meta-analysis results for the relapse rates within 12 months. (A): Network diagram; (B): Cumulative probability ranking curve of different interventions; (C): Forest plot. GCs, glucocorticoids; DMARDs, disease-modifying antirheumatic drugs; WW, Watchful waiting.


A



B



C



Supplementary Figure 4. Network meta-analysis results for the relapse rates over 12 months. (A): Network diagram; (B): Cumulative probability ranking curve of different interventions; (C): Forest plot. GCs, glucocorticoids; DMARDs, disease-modifying antirheumatic drugs; WW, Watchful waiting.

Supplementary Table 1. PRISMA checklist for network meta-analysis

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	1
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	1-2
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	1-2
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	2-5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	2-5
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	2-5
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	2-5
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	2-5
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	2-5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	2-5
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	2-5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	2-5
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	2-5
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	2-5
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	2-5
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	2-5
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	2-5
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	2-5

(Continued)

Supplementary Table 1. PRISMA checklist for network meta-analysis (*Continued*)

Section and Topic	Item #	Checklist item	Location where item is reported
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	2-5
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	2-5
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	5-8
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	5-8
Study characteristics	17	Cite each included study and present its characteristics.	5-8
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	5-8
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	5-8
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	5-8
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	5-8
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	5-8
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	5-8
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	5-8
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	5-8
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	8-10
	23b	Discuss any limitations of the evidence included in the review.	8-10
	23c	Discuss any limitations of the review processes used.	8-10
	23d	Discuss implications of the results for practice, policy, and future research.	8-10
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	N/A
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	N/A
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Title page
Competing interests	26	Declare any competing interests of review authors.	Title page
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Title page

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

Supplementary Table 2. Search strategy for network meta-analysis

2.1. Search strategy of Pubmed	
No.	Search items
#1	((((((((((Immunoglobulin G4-Related Disease[MeSH Terms]) OR (IgG4 Associated Autoimmune Disease*[Title/Abstract])) OR (IgG4 RD[Title/Abstract])) OR (IgG4 Related Disease*[Title/Abstract])) OR (IgG4 related hypertrophic pachymeningitis[Title/Abstract])) OR (IgG4 related pachymeningitis[Title/Abstract])) OR (immunoglobulin G4 related disease*[Title/Abstract])) OR (immunoglobulin G4 related pachymeningitis[Title/Abstract]))
#2	((((((((((Glucocorticoids[MeSH Terms]) OR (glucocortico*[Title/Abstract])) OR (glucocortoid[Title/Abstract])) OR (Glucocorticoid Effects[Title/Abstract])) OR (Glycocortico*[Title/Abstract])) OR (Prednisone[Title/Abstract])) OR (Prednisolone[Title/Abstract])) OR (Methylprednisolone[Title/Abstract])) OR (Dexamethasone[Title/Abstract])) OR (Hydrocortisone[Title/Abstract])) OR (Cortisone[Title/Abstract])) OR (steroid*[Title/Abstract]))
#3	((((((((((((((((((((((((((Immunosuppressive Agents[MeSH Terms]) OR (immune suppress*[Title/Abstract])) OR (immunodepressant[Title/Abstract])) OR (Immunosuppress*[Title/Abstract])) OR (Mycophenolate Mofetil[Title/Abstract])) OR (MMF[Title/Abstract])) OR (Azathioprine[Title/Abstract])) OR (AZA[Title/Abstract])) OR (Cyclophosphamide[Title/Abstract])) OR (CYC[Title/Abstract])) OR (Cytozan[Title/Abstract])) OR (CTX[Title/Abstract])) OR (Leflunomide[Title/Abstract])) OR (LEF[Title/Abstract])) OR (Methotrexate[Title/Abstract])) OR (Amethopterin[Title/Abstract])) OR (MTX[Title/Abstract])) OR (Cyclosporin*[Title/Abstract])) OR (CsA[Title/Abstract])) OR (CyA[Title/Abstract])) OR (Tacrolimus[Title/Abstract])) OR (TAC[Title/Abstract])) OR (iguratimod[Title/Abstract])) OR (IGU[Title/Abstract])) OR (Sulfasalazine[Title/Abstract])) OR (Salicylazosulfapyridine[Title/Abstract])) OR (Sulphasalazine[Title/Abstract])) OR (Salazosulfapyridine[Title/Abstract])) OR (SSZ[Title/Abstract])) OR (Hydroxychloroquine[Title/Abstract])) OR (HCQ[Title/Abstract])) OR (Thalidomide[Title/Abstract])) OR (6-MP[Title/Abstract]))
#4	((((((((((((((B cell depletion therapies[Title/Abstract]) OR (Rituximab[MeSH Terms])) OR (Rituximab*[Title/Abstract])) OR (Mabthera[Title/Abstract])) OR (Rituxan[Title/Abstract])) OR (RTX[Title/Abstract])) OR (obexelimab[Title/Abstract])) OR (inebilizumab[Title/Abstract])) OR (belimumab[Title/Abstract])) OR (rilzabrutinib[Title/Abstract])) OR (Zanubrutinib[Title/Abstract])) OR (Brukinsa[Title/Abstract])) OR (Bortezomib[Title/Abstract])) OR (Lenalidomide[Title/Abstract]))
#5	((((Abatacept[Title/Abstract]) OR (Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin[Title/Abstract])) OR (CTLA4 Ig[Title/Abstract])) OR (CTLA4 immunoglobulin[Title/Abstract])) OR (elotuzumab[Title/Abstract]))
#6	(((((dupilumab[Title/Abstract]) OR (Dupixent[Title/Abstract])) OR (mepolizumab[Title/Abstract])) OR (Bosatria[Title/Abstract])) OR (Nucala[Title/Abstract])) OR (tocilizumab[Title/Abstract]))
#7	prezalumab[Title/Abstract]
#8	((((((((((Janus Kinase Inhibitors[MeSH Terms]) OR (Janus Kinase Inhibitor*[Title/Abstract])) OR (JAK Inhibitor*[Title/Abstract])) OR (baricitinib[Title/Abstract])) OR (tofacitinib[Title/Abstract])) OR (filgotinib[Title/Abstract])) OR (GLPG0634[Title/Abstract])) OR (upadacitinib[Title/Abstract])) OR (Rinvoq[Title/Abstract])) OR (decernotinib[Title/Abstract]))
#9	((((Biological Products[MeSH Terms]) OR (Biologic*[Title/Abstract])) OR (Biopharmaceutical*[Title/Abstract])) OR (Natural Product*[Title/Abstract]))
#10	((disease modifying antirheumatic agent[Title/Abstract]) OR (Disease Modifying Antirheumatic Drug*[Title/Abstract])) OR (DMARD*[Title/Abstract]))
#11	#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
#12	#1 AND #11
#13	((case control[Title/Abstract]) OR (cohort[Title/Abstract])) OR (Retrospect*[Title/Abstract])) OR (Prospect*[Title/Abstract]))
#14	#12 AND #13
2.2. Search strategy of Embase	
No.	Search items
#1	'immunoglobulin g4 related disease'/exp OR 'igg4 associated autoimmune disease':ab,ti OR 'igg4 rd':ab,ti OR 'igg4 related disease':ab,ti OR 'igg4 related hypertrophic pachymeningitis':ab,ti OR 'igg4 related pachymeningitis':ab,ti OR 'immunoglobulin g4 related disease':ab,ti OR 'immunoglobulin g4 related pachymeningitis':ab,ti
#2	'glucocorticoid'/exp OR glucocortico*:ab,ti OR glucocortoid:ab,ti OR 'glucorticoid effects':ab,ti OR glycocortico*:ab,ti OR prednisone:ab,ti OR prednisolone:ab,ti OR methylprednisolone:ab,ti OR dexamethasone:ab,ti OR hydrocortisone:ab,ti OR cortisone:ab,ti OR steroid*:ab,ti

(Continued)

Supplementary Table 2. Search strategy for network meta-analysis (*Continued*)

#3	'immunosuppressive agent'/exp OR 'immune suppress*':ab,ti OR immunodepressant:ab,ti OR immunosuppress*:ab,ti OR 'mycophenolate mofetil':ab,ti OR mmf:ab,ti OR azathioprine:ab,ti OR aza:ab,ti OR cyclophosphamide:ab,ti OR cyc:ab,ti OR cytoxan:ab,ti OR ctx:ab,ti OR leflunomide:ab,ti OR lef:ab,ti OR methotrexate:ab,ti OR amethopterin:ab,ti OR mtx:ab,ti OR cyclosporin*:ab,ti OR csa:ab,ti OR cya:ab,ti OR tacrolimus:ab,ti OR tac:ab,ti OR iguratimod:ab,ti OR igu:ab,ti OR salazosulfapyridine:ab,ti OR salicylazosulfapyridine:ab,ti OR sulphasalazine:ab,ti OR ssz:ab,ti OR hydroxychloroquine:ab,ti OR hcq:ab,ti OR thalidomide:ab,ti OR '6 mp':ab,ti
#4	'b cell depletion therapies':ab,ti OR 'rituximab'/exp OR rituximab*:ab,ti OR mabthera:ab,ti OR rituxan:ab,ti OR rtx:ab,ti OR obexelimab:ab,ti OR inebilizumab:ab,ti OR belimumab:ab,ti OR rilzabrutinib:ab,ti OR zanubrutinib:ab,ti OR bruksina:ab,ti OR bortezomib:ab,ti OR lenalidomide:ab,ti
#5	abatacept:ab,ti OR 'cytotoxic t lymphocyte associated antigen 4 immunoglobulin':ab,ti OR 'ctla4 ig':ab,ti OR 'ctla4 immunoglobulin':ab,ti OR elotuzumab:ab,ti
#6	dupilumab:ab,ti OR dupixent:ab,ti OR mepolizumab:ab,ti OR bosatria:ab,ti OR nucala:ab,ti OR tocilizumab:ab,ti
#7	prezalumab:ab,ti
#8	'janus kinase inhibitor'/exp OR 'janus kinase inhibitor*':ab,ti OR 'jak inhibitor*':ab,ti OR baricitinib:ab,ti OR tofacitinib:ab,ti OR filgotinib:ab,ti OR glpg0634:ab,ti OR upadacitinib:ab,ti OR rinvoq:ab,ti OR decernotinib:ab,ti
#9	'biological product'/exp OR biologic*:ab,ti OR biopharmaceutical*:ab,ti OR 'natural product*':ab,ti
#10	'disease modifying antirheumatic drug'/exp OR 'disease modifying antirheumatic agent':ab,ti OR 'disease modifying antirheumatic drug*':ab,ti OR dmard*:ab,ti
#11	#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
#12	#1 AND #11
#13	'case control':ab,ti OR cohort:ab,ti OR retrospect*:ab,ti OR prospect*:ab,ti
#14	#12 AND #13
2.3. Search strategy of Cochrane Library	
No.	Search items
#1	MeSH descriptor: [Immunoglobulin G4-Related Disease] explode all trees
#2	(IgG4 Associated Autoimmune Disease*):ti,ab,kw OR (IgG4 RD):ti,ab,kw OR (IgG4 Related Disease*):ti,ab,kw OR (IgG4 related hypertrophic pachymeningitis):ti,ab,kw OR (IgG4 related pachymeningitis):ti,ab,kw OR (immunoglobulin G4 related disease*):ti,ab,kw OR (immunoglobulin G4 related pachymeningitis):ti,ab,kw
#3	#1 AND #2
#4	MeSH descriptor: [Glucocorticoids] explode all trees
#5	(glucocortico*):ti,ab,kw OR (glucocortoid):ti,ab,kw OR (Glucocorticoid Effects):ti,ab,kw OR (Glycocortico*):ti,ab,kw OR (Prednisone):ti,ab,kw OR (Prednisolone):ti,ab,kw OR (Methylprednisolone):ti,ab,kw OR (Dexamethasone):ti,ab,kw OR (Hydrocortisone):ti,ab,kw OR (Cortisone):ti,ab,kw OR (steroid*):ti,ab,kw
#6	#4 AND #5
#7	MeSH descriptor: [Immunosuppressive Agents] explode all trees
#8	(immune suppress*):ti,ab,kw OR (immunodepressant):ti,ab,kw OR (Immunosuppress*):ti,ab,kw OR (Mycophenolate Mofetil):ti,ab,kw OR (MMF):ti,ab,kw OR (Azathioprine):ti,ab,kw OR (AZA):ti,ab,kw OR (Cyclophosphamide):ti,ab,kw OR (CYC):ti,ab,kw OR (Cytoxan):ti,ab,kw OR (CTX):ti,ab,kw OR (Leflunomide):ti,ab,kw OR (LEF):ti,ab,kw OR (Methotrexate):ti,ab,kw OR (Amethopterin):ti,ab,kw OR (MTX):ti,ab,kw OR (Cyclosporine):ti,ab,kw OR (Cyclosporin*):ti,ab,kw OR (CsA):ti,ab,kw OR (CyA):ti,ab,kw OR (Tacrolimus):ti,ab,kw OR (TAC):ti,ab,kw OR (iguratimod):ti,ab,kw OR (IGU):ti,ab,kw OR (Sulfasalazine):ti,ab,kw OR (Salicylazosulfapyridine):ti,ab,kw OR (Sulphasalazine):ti,ab,kw OR (Salazosulfapyridine):ti,ab,kw OR (SSZ):ti,ab,kw OR (Hydroxychloroquine):ti,ab,kw OR (HCQ):ti,ab,kw OR (Thalidomide):ti,ab,kw
#9	#7 AND #8
#10	MeSH descriptor: [Rituximab] explode all trees
#11	(B cell depletion therapies):ti,ab,kw OR (Rituximab*):ti,ab,kw OR (Mabthera):ti,ab,kw OR (Rituxan):ti,ab,kw OR (RTX):ti,ab,kw OR (obexelimab):ti,ab,kw OR (inebilizumab):ti,ab,kw OR (belimumab):ti,ab,kw OR (rilzabrutinib):ti,ab,kw OR (Zanubrutinib):ti,ab,kw OR (Bruksina):ti,ab,kw OR (Bortezomib):ti,ab,kw OR (Lenalidomide):ti,ab,kw
#12	#10 AND #11
#13	(Abatacept):ti,ab,kw OR (Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin):ti,ab,kw OR (CTLA4 Ig):ti,ab,kw OR (CTLA4 immunoglobulin):ti,ab,kw OR (elotuzumab):ti,ab,kw

(Continued)

Supplementary Table 2. Search strategy for network meta-analysis (*Continued*)

#14	(dupilumab):ti,ab,kw OR (Dupixent):ti,ab,kw OR (mepolizumab):ti,ab,kw OR (Bosatria):ti,ab,kw OR (Nucala):ti,ab,kw OR (tocilizumab):ti,ab,kw
#15	(prezalumab):ti,ab,kw
#16	MeSH descriptor: [Janus Kinase Inhibitors] explode all trees
#17	(Janus Kinase Inhibitor*):ti,ab,kw OR (JAK Inhibitor*):ti,ab,kw OR (baricitinib):ti,ab,kw OR (tofacitinib):ti,ab,kw OR (GLPG0634):ti,ab,kw OR (filgotinib):ti,ab,kw OR (upadacitinib):ti,ab,kw OR (Rinvoq):ti,ab,kw OR (decernotinib):ti,ab,kw
#18	#16 AND #17
#19	MeSH descriptor: [Biological Products] explode all trees
#20	(Biologic*):ti,ab,kw OR (Biopharmaceutical*):ti,ab,kw OR (Natural Product*):ti,ab,kw
#21	#19 AND #20
#22	(disease modifying antirheumatic drug):ti,ab,kw OR (disease modifying antirheumatic agent):ti,ab,kw OR (Disease Modifying Antirheumatic Drug*):ti,ab,kw OR (DMARD*):ti,ab,kw
#23	#6 AND #9 AND #12 AND #13 AND #14 AND #15 AND #18 AND #21 AND #22
#24	(case control):ti,ab,kw OR (cohort):ti,ab,kw OR (retrospect*):ti,ab,kw OR (prospect*):ti,ab,kw
#25	#3 AND #23 AND #24

2.4. Search strategy of Web of Science

No.	Search items
#1	immunoglobulin G4 related disease (Topic) OR IgG4 Associated Autoimmune Disease* (Topic) OR IgG4 RD (Topic) OR IgG4 Related Disease* (Topic) OR IgG4 related hypertrophic pachymeningitis (Topic) OR IgG4 related pachymeningitis (Topic) OR immunoglobulin G4 related disease* (Topic) OR immunoglobulin G4 related pachymeningitis (Topic)
#2	glucocortico* (Topic) OR glucocortoid (Topic) OR Glucocorticoid Effects (Topic) OR Glycocortico* (Topic) OR prednisone (Topic) OR prednisolone (Topic) OR methylprednisolone (Topic) OR dexamethasone (Topic) OR hydrocortisone (Topic) OR cortisone (Topic) OR steroid* (Topic)
#3	immunosuppressive agent (Topic) OR immune suppress* (Topic) OR immunodepressant (Topic) OR Immunosuppress* (Topic) OR mycophenolate mofetil (Topic) OR MMF (Topic) OR azathioprine (Topic) OR AZA (Topic) OR cyclophosphamide (Topic) OR CYC (Topic) OR Cytoxan (Topic) OR CTX (Topic) OR leflunomide (Topic) OR LEF (Topic) OR methotrexate (Topic) OR Amethopterin (Topic) OR MTX (Topic) OR Cyclosporin* (Topic) OR CsA (Topic) OR CyA (Topic) OR tacrolimus (Topic) OR TAC (Topic) OR iguratimod (Topic) OR IGU (Topic) OR Sulfasalazine (Topic) OR salazosulfapyridine (Topic) OR Salicylazosulfapyridine (Topic) OR Sulphasalazine (Topic) OR Salazosulfapyridine (Topic) OR SSZ (Topic) OR hydroxychloroquine (Topic) OR HCQ (Topic) OR thalidomide (Topic) OR 6-MP (Topic)
#4	B cell depletion therapies (Topic) OR Rituximab* (Topic) OR Mabthera (Topic) OR Rituxan (Topic) OR RTX (Topic) OR obexelimab (Topic) OR inebilizumab (Topic) OR belimumab (Topic) OR rilzabrutinib (Topic) OR zanubrutinib (Topic) OR Brukinsa (Topic) OR bortezomib (Topic) OR lenalidomide (Topic)
#5	abatacept (Topic) OR Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin (Topic) OR CTLA4 Ig (Topic) OR CTLA4 immunoglobulin (Topic) OR elotuzumab (Topic)
#6	dupilumab (Topic) OR Dupixent (Topic) OR mepolizumab (Topic) OR Bosatria (Topic) OR Nucala (Topic) OR tocilizumab (Topic)
#7	prezalumab (Topic)
#8	Janus Kinase Inhibitor* (Topic) OR JAK Inhibitor* (Topic) OR baricitinib (Topic) OR tofacitinib (Topic) OR GLPG0634 (Topic) OR filgotinib (Topic) OR upadacitinib (Topic) OR Rinvoq (Topic) OR decernotinib (Topic)
#9	biological product* (Topic) OR Biologic* (Topic) OR Biopharmaceutical* (Topic) OR Natural Product* (Topic)
#10	Disease Modifying Antirheumatic Drug* (Topic) OR disease modifying antirheumatic agent (Topic) OR DMARD* (Topic)
#11	case control (Topic) OR cohort (Topic) OR retrospect* (Topic) OR prospect* (Topic)
#12	#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
#13	#1 AND #11 AND #12

Supplementary Table 3. Characteristics of the included studies

Author	Year	Country	Age (mean ± SD, years)		Total number	Treatment			Treatment D	Dose of GCs	Type of DMARDs	Median follow-up time (months)	Main organs involvement	Outcome	NOS score
						A	B	C							
Ghazale[24]	2008	USA	59.9±15.7		53	GCs	GCs+DMARDs			Started with 40 mg/d for 4 weeks, tapered by 5 mg/wk	AZA, MMF, CTX	6	Cholangitis	③	7
Kubota[25]	2011	Japan	65.9±11.2		70	GCs	WW			NA	NA	46.9	Pancreatitis	③	7
Ebbo[16]	2012	France	56.8±15.0		25	GCs	DMARDs			Started with 0.6mg/kg/d	AZA, CTX, MTX, RTX	60.4	Systemic	①	8
Hart[26]	2012	USA	64.7±14.1		116	GCs	DMARDs	GCs+DMARDs		Started with 40 mg/d for 4 weeks, tapered 5 mg/wk until discontinued	AZA, 6-MP, MMF, RTX	47	Pancreatitis	③	9
Huggett[27]	2014	UK	59.9±13.5		115	GCs	GCs+DMARDs			Started with 30-40 mg/d	AZA, MMF, MTX, 6-MP	33	Pancreatitis and cholangitis	③	7
Carruthers[19]	2015	USA	61.0±11.0		30	DMARDs	GCs+DMARDs			NA	CTX	6	Systemic	①	8
Nada[28]	2016	India	46.6±16.3		10	GCs	GCs+DMARDs			NA	CTX	12	Kidney	①	7
Sekiguchi[6]	2016	USA	59.9±15.7		166	GCs	GCs+DMARDs			Started with 0.4-0.7 mg/kg/d	AZA, 6-MP, MMF, RTX	29	Systemic	③	8
Sun[29]	2016	China	44.8±15.0		17	GCs	GCs+DMARDs			Started with 20-50 mg/d	AZA, CTX, MMF	18	Lung	②②	8
Wallace[30]	2016	USA	55.9±13.2		57	DMARDs	GCs+DMARDs			NA	CTX	8	Systemic	③	7
Chen[31]	2017	China	62.5±16.1		14	GCs	GCs+DMARDs			NA	AZA	23	Pancreatitis	③	7
Karadag[32]	2017	Turkey	51.1±12.7		37	GCs	GCs+DMARDs			Started with 0.5–0.6 mg/kg/d in patients with localized involvement and 1 mg/kg/d in patients with multiorgan involvement	CTX	18	Systemic	②③	7
Yunyun[12]	2017	China	51.6±12.4		102	GCs	GCs+DMARDs			Started with 0.5–1.0mg/kg/d for 1 month, tapered by 5mg per 2 weeks, maintained at 5–10mg/d	CTX	12	Systemic	②③③	9
Fernández-Codina[23]	2018	Spain	55.2±19.7		68	GCs	DMARDs			NA	AZA, MMF	36	Systemic	②③	8
Hong[33]	2018	China	51.8±14.4		43	GCs	GCs+DMARDs			Started with 200 mg/d, followed by 0.6 mg/kg/d, tapered by 2.5-5 mg, maintained at 5 mg/d	CTX, AZA, LEF, MMF	24.6	Salivary	③③	8
Karim[34]	2018	Netherlands	54.7±14.5		32	GCs	DMARDs	GCs+DMARDs		Started with 0.5-1mg/kg/d	CTX, MMF, MTX, AZA, Cya, RTX, thalidomide	12	Systemic	③	8
Park[35]	2018	Korea	55.2(Median)		42	GCs	GCs+DMARDs			Started with 0.6–0.8mg/kg/d, tapered by 10mg every 2–4 weeks	AZA, MTX, Cya	24	Ophthalmic	③	7
Wallwork[36]	2018	USA	53.8±3.8		26	DMARDs	GCs+DMARDs			Started with 20– 80mg/day	CTX	6	Retroperitoneal fibrosis	③	7
Wang[37]	2018	China	53.5±13.4		215	GCs	GCs+DMARDs			Started with 0.5-1.0 mg/kg/d, tapered by 5 mg, maintained at 5-10 mg/d	CTX, MMF, MTX, AZA, LEF, Cya, T2	6	Systemic	②③③	9
Xin[38]	2018	China	59.0±11.1		101	GCs	GCs+DMARDs			Started with 0.6 mg/kg/d, tapered by 5 mg every 1 to 2 weeks	AZA, MMF	40	Pancreatitis	③	8
Fei[11]	2019	China	56.0±12.2		69	GCs	GCs+DMARDs			Started with 0.6–0.8 mg/kg/d for 1 month, tapered by 5mg per 2 weeks, maintained at 7.5-10mg/d	MMF	12	Systemic	②③③	9

(Continued)

Supplementary Table 3. Characteristics of the included studies (Continued)

Author	Year	Country	Age (mean ± SD, years)		Total number	Treatment			Treatment		Dose of GCs	Type of DMARDs	Median follow-up time (months)	Main organs involvement	Outcome	NOS score
			A	B		C	D									
Peng[39]	2019	China	51.9±13.3		122	GCs	GCs+DMARDs			Started with 0.6-1.0 mg/kg/d, tapered by 5 mg per 1 or 2 weeks	CTX, MMF, MTX, AZA, LEF, CyA	12	Systemic	②	9	
Liu[40]	2020	China	57.9±2.3		277	GCs	GCs+DMARDs			Started with 0.6-0.8 mg/kg/d, tapered by 5 mg, maintained at 5-10 mg/d	CTX, MMF, MTX, AZA, LEF	21	Systemic	②	9	
Phaopraphat[41]	2020	Thailand	59.6±13.3		110	GCs	GCs+DMARDs			NA	CTX, MMF, MTX, AZA, RTX	22.2	Systemic	②	7	
Gan[15]	2021	China	51.7±11.1		132	GCs	DMARDs	GCs+DMARDs	WW	Started with 0.6-1.0 mg/kg/d, tapered by 5 mg, maintained at ≤10 mg/d	CTX, MMF, MTX	6	Ophthalmic	①②	8	
Peng[42]	2021	China	53.8±12.5		143	GCs	GCs+DMARDs			Started with 0.5-1.0 mg/kg/d	CTX, MMF, MTX, LEF	24	Systemic	②	8	
Zongfei[43]	2021	China	58.7±3.0		102	GCs	GCs+DMARDs	WW		Started with 0.6-1.0 mg/kg/d, gradually tapered to a maintenance dose of 0.1-0.2 mg/kg/d	CTX, AZA, RTX	21	Systemic	①②	8	
An[44]	2022	China	62.0±12.8		92	GCs	WW			NA	NA	11	Systemic	①	8	
Kubota[45]	2022	Japan	NA		896	GCs	WW			Started with 0.6 mg/kg/d, maintained at 5-10mg/d	NA	45	Cholangitis	①②	7	
Matza[9]	2022	USA	64.8±12.2		10	DMARDs	GCs+DMARDs			NA	Abatacept	6	Systemic	①	7	
Son[46]	2022	Korea	50.9±9.2		38	GCs	GCs+DMARDs			NA	MTX, CyA, AZA	33.6	Ophthalmic	①	7	
Chaba[47]	2023	France, Belgium	67.8±3.8		101	GCs	GCs+DMARDs			Started with a mean dose of 0.8±0.3 mg/kg/d	RTX	12	Kidney	③③	8	
Overbeek[48]	2023	Europe	57.0±20.0		735	GCs	DMARDs	WW		Started with 40 mg/d	AZA, MTX, RTX	30	Pancreatitis	①②	8	
Zhang[14]	2023	China	57.6±12.8		171	GCs	GCs+DMARDs			Started with 30-40 mg/d for 1 month, tapered by 5mg per 1 or 2 weeks, maintained at 2.5-5.0mg/d	CTX, MMF, MTX, TAC, triptolide	12	Systemic	①②	9	

Note: GCs, glucocorticoids; DMARDs, disease-modifying antirheumatic drugs; WW, Watchful waiting; AZA, azathioprine; CTX, cyclophosphamide; MMF, mycophenolate mofetil; MTX, methotrexate; LEF, leflunomide; RTX, Rituximab; TAC, tacrolimus; CyA, cyclosporine A; T2, tripterysium glycosides; 6-MP, 6-mercaptopurine; NA, not available; ①, remission; ②, relapse; ③, adverse reactions.

Supplementary Table 4. Qualitative analysis of adverse events by system organ class

Organ System	Adverse Event		GCs+DMARDs (n=285)		DMARDs (n=19)		GCs (n=252)	
	Gastrointestinal		23 (8.1%)		0 (0%)		12 (4.8%)	
Liver	Impaired hepatic function		6 (2.1%)		0 (0%)		6 (2.4%)	
Metabolic	Glucose intolerance		31 (10.9%)		0 (0%)		25 (9.9%)	
Infection	Infections		43 (15.1%)		1 (5.3%)		38 (15.1%)	
Cardiovascular	Hypertension		2 (0.7%)		0 (0%)		3 (1.2%)	
Hematological	Leukopenia/Myelosuppression		6 (2.1%)		0 (0%)		0 (0%)	

Supplementary Table 5. Organ involvement in different regional cohorts

Affecting organ or tissue	Asian cohorts (n=1634)	Non-Asian cohorts (n=440)
Lymph gland	681(41.68%)	109(24.77%)
Salivary glands	677(41.43%)	105(23.86%)
Pancreas	587(35.92%)	179(40.68%)
Bile duct	466(28.52%)	126(28.64%)
Lacrimal gland	395(24.17%)	47(10.68%)
Lung/pleura	386(23.62%)	66(15.00%)
Orbit	287(17.56%)	73(16.59%)
Retroperitoneal fibrosis	269(16.46%)	91(20.68%)
Nose	243(14.87%)	38(8.64%)
Kidney	173(10.59%)	60(13.64%)
Prostate	125(7.65%)	9(2.05%)
Aorta	69(4.22%)	47(10.68%)
Thyroid	58(3.55%)	12(2.73%)
Liver	29(1.77%)	23(5.23%)
Mediastina	26(1.59%)	10(2.27%)
Pituitary	12(0.73%)	4(0.91%)
Mater	12(0.73%)	6(1.36%)
Skin	12(0.73%)	12(2.73%)
Gastrointestinal tract	10(0.61%)	12(2.73%)
Ear	3(0.18%)	4(0.91%)
Pericardium	1(0.06%)	13(2.95%)
Breast	1(0.06%)	2(0.45%)

Supplementary Table 6. Subgroup analysis in a network frame by region

A				
GCs+DMARDs	RR(95% CI)			
1.15 (0.95, 1.39)	GCs			
0.99 (0.62, 1.69)	0.86 (0.54, 1.47)	DMARDs		
1.83 (1.26, 2.62)	1.6 (1.13, 2.21)	1.85 (1, 3.17)	WW	
B				
GCs+DMARDs	RR(95% CI)			
0.62 (0.44, 0.85)	GCs			
0.61 (0.22, 1.68)	0.99 (0.37, 2.74)	DMARDs		
0.64 (0.35, 1.22)	1.04 (0.6, 1.91)	1.05 (0.36, 3.11)	WW	
C				
GCs+DMARDs	RR(95% CI)			
1.32 (0.59, 3.99)	GCs			
1.33 (0.66, 3.77)	0.99 (0.67, 1.47)	DMARDs		
D				
GCs+DMARDs	RR(95% CI)			
0.54 (0.33, 0.87)	GCs			
0.65 (0.31, 1.48)	1.2 (0.59, 2.84)	DMARDs		

Note: (A): the overall remission rates in Asian patients; (B): the overall relapse rates in Asian patients; (C): the overall remission rates in Non-Asian patients; (D): the overall relapse rates in Non-Asian patients. The cells contain the RR (95% CI) of the medication protocol on the left compared to the medication protocol on the right. Bolded values are statistically significant. GCs, glucocorticoids; DMARDs, disease-modifying antirheumatic drugs; WW, Watchful waiting.

Note: (A): the overall remission rates in Asian patients; (B): the overall relapse rates in Asian patients; (C): the overall remission rates in Non-Asian patients; (D): the overall relapse rates in Non-Asian patients. The cells contain the RR (95% CI) of the medication protocol on the left compared to the medication protocol on the right. Bolded values are statistically significant. GCs, glucocorticoids; DMARDs, disease-modifying antirheumatic drugs; WW, Watchful waiting.

Supplementary Table 7. Subgroup analysis in a network frame by different DMARDs

A					
GCs+cDMARDs	RR(95% CI)				
1.05 (0.61, 1.89)	GCs+bDMARDs				
1.20 (0.85, 1.74)	1.14 (0.59, 2.17)	cDMARDs			
0.85 (0.57, 1.29)	0.81 (0.41, 1.53)	0.71 (0.49, 1.03)	bDMARDs		
1.15 (0.94, 1.41)	1.09 (0.59, 1.93)	0.95 (0.68, 1.30)	1.34 (0.92, 1.93)	GCs	
1.72 (1.26, 2.39)	1.63 (0.85, 3.07)	1.43 (0.94, 2.15)	2.01 (1.28, 3.18)	1.50 (1.14, 2.00)	WW
B					
GCs+cDMARDs	RR(95% CI)				
1.47 (0.44, 5.62)	GCs+bDMARDs				
0.63 (0.30, 1.40)	0.43 (0.11, 1.58)	cDMARDs			
1.11 (0.33, 4.46)	0.76 (0.23, 2.49)	1.74 (0.53, 6.80)	bDMARDs		
0.59 (0.43, 0.80)	0.40 (0.11, 1.29)	0.93 (0.43, 1.90)	0.53 (0.13, 1.73)	GCs	
0.88 (0.47, 1.66)	0.60 (0.14, 2.22)	1.38 (0.56, 3.38)	0.79 (0.18, 2.96)	1.50 (0.85, 2.71)	WW

Note: (A): the overall remission rates between different medication protocols; (B): the overall relapse rates between different medication protocols; The cells contain the RR (95% CI) of the medication protocol on the left compared to the medication protocol on the right. Bolded values are statistically significant. GCs, glucocorticoids; cDMARDs, conventional disease-modifying antirheumatic drugs; bDMARDs, biological conventional disease-modifying antirheumatic drugs; WW, Watchful waiting